| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 13,290 | 11,490 | 9,890 | 9,380 | 9,480 |
| Sales Growth | +15.67% | +16.18% | +5.44% | -1.05% | -90.11% |
| Net Income | -48,220 | -38,270 | -36,640 | -33,030 | -30,800 |
| Net Income Growth | -26.00% | -4.45% | -10.93% | -7.24% | -162.56% |
Gossamer Bio Inc (GOSS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Gossamer Bio Inc. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutics in the areas of immunology, inflammation and oncology. The company's product pipeline includes GB001, GB002, GB004, GB1275, Autoimmune program and Oncology program which are in clinical stage. Gossamer Bio Inc. is based in San Diego, California.
Fiscal Year End Date: 12/31